• Login
    View Item 
    •   Athenaeum Home
    • BioMed Central Open Access Articles
    • Open Access Articles by UGA Faculty
    • View Item
    •   Athenaeum Home
    • BioMed Central Open Access Articles
    • Open Access Articles by UGA Faculty
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany - an application of the efficiency frontier approach

    Thumbnail
    View/Open
    12879_2015_Article_1048.pdf (862.6Kb)
    Date
    2015-07-30
    Author
    Gissel, Christian
    Götz, Georg
    Mahlich, Jörg
    Repp, Holger
    Metadata
    Show full item record
    Abstract
    Abstract Background The approval of direct-acting antivirals for Interferon-free treatment revolutionized the therapy of chronic Hepatitis C infection. As of August 2014, two treatment regimens for genotype 1 infection received conditional approval in the European Union: Sofosbuvir and Ribavirin for 24 weeks and Sofosbuvir and Simeprevir with or without Ribavirin for 12 weeks. We aim to analyze the cost-effectiveness of both regimens in Germany. Methods We set up a Markov model with a lifetime horizon to simulate immediate treatment success and long-term disease progression for treatment-naive patients. The model analyzes both short-term and long-term costs and benefits from the perspective of the German Statutory Health Insurance. We apply the efficiency frontier method, which was suggested by German Institute for Quality and Efficiency in Health Care for cost-effectiveness analysis in Germany. Results The efficiency frontier is defined by dual therapy and first generation direct-acting antiviral Boceprevir, yielding a maximum of € 1,447.69 per additional percentage point of sustained virologic response gained. Even without rebates, Sofosbuvir/Simeprevir is very close with € 1,560.13 per additional percentage point. It is both more effective and less expensive than Sofosbuvir/Ribavirin. Conclusions In addition to higher sustained virologic response rates, new direct-acting antivirals save long-term costs by preventing complications such as liver cirrhosis, hepatocellular carcinoma and ultimately liver transplants, thereby offsetting part of higher drug costs. Our findings are in line with the guidance published by German Society for Gastroenterology, Digestive and Metabolic Diseases, which recommends Sofosbuvir/Simeprevir for Interferon ineligible or intolerant patients.
    URI
    http://dx.doi.org/10.1186/s12879-015-1048-z
    http://hdl.handle.net/10724/31774
    Collections
    • Open Access Articles by UGA Faculty

    About Athenaeum | Contact Us | Send Feedback
     

     

    Browse

    All of AthenaeumCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    About Athenaeum | Contact Us | Send Feedback